Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122

Benzinga · 2d ago
Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $124 to $122.